levodopa has been researched along with atipamezole in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haapalinna, A; Männistö, PT; Sirviö, J; Yavich, L; Ylinen, A | 1 |
| Haapalinna, A; Heinonen, E; Leino, T | 1 |
| Bhide, N; Bishop, C; Conti, M; George, JA; Hallmark, J; Ostock, CY; Palumbo, N | 1 |
3 other study(ies) available for levodopa and atipamezole
| Article | Year |
|---|---|
Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Caudate Nucleus; Corpus Striatum; Dopamine; Drug Synergism; Electric Stimulation; Imidazoles; Levodopa; Male; Nucleus Accumbens; Rats; Rats, Wistar; Time Factors | 2003 |
The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Cardiovascular System; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Imidazoles; Levodopa; Male; Movement; Rats; Rats, Sprague-Dawley; Time Factors | 2003 |
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinson Agents; Clonidine; Dyskinesia, Drug-Induced; Imidazoles; Levodopa; Locus Coeruleus; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2 | 2015 |